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Supplementary Table 1. Assessment of the risk of bias in accordance with the Cochrane 52 
Collaboration tool* 53 
Study Sequence 
generation 
Allocation 
concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other 
sources of 
bias 
Calabrese 
2015 [20] 
Unclear Unclear Unclear Yes Yes Yes 
Durgam 
2014 [16] 
Unclear Unclear Unclear Unclear Yes Yes 
Durgam 
2015a [19] 
Unclear Unclear Unclear Yes Yes Yes 
Durgam 
2015b 
[21] 
Yes Yes Yes Yes Yes Yes 
Durgam 
2015c [15] 
Unclear Unclear Unclear Yes Yes Yes 
Durgam 
2015d 
[17] 
Unclear Unclear Unclear Yes Yes Yes 
Kane 2015 
[14] 
Unclear Unclear Unclear Yes Yes Yes 
Sachs 
2015 [18] 
Unclear Unclear Unclear Yes Yes Yes 
Durgam 
2016 [22] 
Yes Yes Yes Yes Yes Yes 
*Yes: low risk of bias. These domains were considered to be less vulnerable to bias for 54 
following reasons: detailed methods of randomization were reported clearly; there was no 55 
missing data or missing outcome data was balanced across intervention groups or had been 56 
imputed using statistical methods; the outcomes were pre-specified and reported or; the 57 
study appeared to be free of other sources of bias. For example, Durgam 2015b [21] used 58 
computer-generated randomization list for sequence generation, and the study drug was 59 
identical in appearance. Durgam 2016 [22] reported that an interactive voice/web system 60 
was applied to generate a randomization list and study drug was identical in appearance. 61 
Therefore, risk of bias in respective domains were rated as “low risk of bias.” 62 
Unclear: domains were marked “unclear risk of bias” due to insufficient information 63 
reported. For example, subjects in these studies were randomly assigned, however the 64 
details of methods applied in sequence generation, allocation concealment and blinding 65 
were not reported. In Durgam 2014, the number of subjects who discontinued treatment in 66 
cariprazine and placebo groups were different, which might affect the estimation of safety 67 
outcomes as they were analyzed based on safety population, however the effect was not 68 
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clear. The details of the quality assessment criteria were based on the Cochrane handbook 69 
[45].70 
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 71 
*Criteria for GRADE quality assessments: 1) risk of bias: outcomes reported by trials with randomization or double-blinding were rated “not 72 
serious”. Outcomes reported by trials using randomization methods suffer from high risk of bias or single-blinding method were rated “serious”. 73 
Outcomes reported by trials without randomization or blinding design were rated “very serious”; 74 
Supplementary Table 2. Evidence profile table
R e la t iv e A bs o lute
(9 5 % C I) (9 5 % C I)
R R  1.13 11 m o re  pe r 1,0 0 0 ⨁⨁◯◯
(0.77 to  1.66) (fro m 20 fewer to  58 mo re) LOW
R R  1.6 8 16  m o re  pe r 1,0 0 0 ⨁⨁⨁⨁
(1.12 to  2.52) (fro m 3 mo re  to  35 mo re) HIGH
R R  3 .3 6 110  m o re  pe r 1,0 0 0 ⨁⨁⨁⨁
(2.48 to  4.56) (fro m 69 mo re  to  166 mo re) HIGH
R R  3 .3 4 6 7  m o re  pe r 1,0 0 0 ⨁⨁⨁⨁
(2.17 to  5.13) (fro m 34 mo re  to  119 mo re) HIGH
R R  3 .7 1 5 9  m o re  pe r 1,0 0 0 ⨁⨁⨁⨁
(2.04 to  6.73) (fro m 22 mo re  to  124 mo re) HIGH
R R  2 .7 9 18 2  m o re  pe r 1,0 0 0 ⨁⨁◯◯
(1.63 to  4.75) (fro m 64 mo re  to  381 mo re) LOW
R R  0 .9 3 9  fe we r pe r 1,0 0 0 ⨁⨁⨁◯
(0.76 to  1.13) (fro m 17 mo re  to  31 fewer) MODERATE
C I:  Co nfidence  inte rva l; R R :  Ris k ra tio
1. Mo dera te  he tero geneity (I-s quare  > 50%) was  de tec ted
2. Number o f pa tients  inc luded in this  review is  les s  than the  o ptimal info rmatio n s ize
3. Us e  o f be ta-blo ckers  medica tio n was  us ed as  a  s urro gate  o f advers e  event o f aka this ia
4. Us e  o f anti-P arkins o n medica tio n was  us ed as  a  s urro gate  o f advers e  event o f P arkins o nis m
s erio us  2 no ne 250/2107 (11.9%) 144/1100 (13.1%) CRITICAL
no ne 285/1171 (24.3%) 72/709 (10.2%) CRITICAL
Ortho s ta tic  hypo tens io n (fo llo w up: range  3 weeks  to  8)
7 rando mis ed tria ls no t s erio us no t s erio us no t s erio us
5 rando mis ed tria ls no t s erio us s erio us  1 s erio us  4 no t s erio us
no t s erio us s tro ng as s o c ia tio n 85/1013 (8.4%) 12/555 (2.2%) CRITICAL
Us e o f anti-P arkins o n medica tio n (fo llo w up: range  3 weeks  to  6 weeks )
s tro ng as s o c ia tio n 225/2334 (9.6%) 33/1146 (2.9%) CRITICAL
Us e o f be ta-blo ckers  medica tio n (fo llo w up: range  3 weeks  to  6 weeks )
4 rando mis ed tria ls no t s erio us no t s erio us s erio us  3
8 rando mis ed tria ls no t s erio us no t s erio us no t s erio us no t s erio us
no t s erio us s tro ng as s o c ia tio n 448/2880 (15.6%) 66/1412 (4.7%) CRITICAL
Treatment-emergent parkins o nis m (fo llo w up: range  3 weeks  to  8 weeks )
no ne 122/2627 (4.6%) 30/1285 (2.3%) CRITICAL
Treatment-emergent aka this ia  (fo llo w up: range  3 weeks  to  8 weeks )
9 rando mis ed tria ls no t s erio us no t s erio us no t s erio us
8 rando mis ed tria ls no t s erio us no t s erio us no t s erio us no t s erio us
s erio us  2 no ne 285/2900 (9.8%) 125/1424 (8.8%) CRITICAL
P o tentia lly c linica lly s ignificant change  in weight (fo llo w up: range  3 weeks  to  8 weeks )
Im pre c is io n Othe r c o ns ide ra t io ns c a ripra zine pla c e bo
Dis co ntinuatio n due  to  AEs  (fo llo w up: range  3 weeks  to  8 weeks )
9 rando mis ed tria ls no t s erio us s erio us  1 no t s erio us
Qua lity a s s e s s m e nt № o f  pat ients Effe c t
Qua lity Im po rta nc e
№ o f  studies S tudy de s ig n R is k o f  bia s Inc o ns is te nc y Indire c tne s s
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2) Inconsistency: I2 statistic was used as the main statistic to measure consistency for outcomes in this study. Outcomes with I2 below 50%, 75 
between 50% and 75%, and above 75% were rated “not serious”, “serious” and “very serious”, respectively; 76 
3) Indirectness: outcomes without any indirectness in study population, intervention or outcome measurements were rated as “not serious”. 77 
Outcomes with only indirectness detected in outcome measurements were rated “serious”. Outcomes with indirectness detected in both outcome 78 
measurements and study population were rated “very serious”; 79 
4) Imprecision: Optimal information size was calculated using online calculator (http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html). Outcomes 80 
with the number of included patients not less than optimal information size were graded “not serious”. Outcomes with the number of included 81 
patient with less than optimal information size were graded “serious”; 82 
5) Other considerations: Dose-dependent response was assessed where possible; publication bias was assessed if more than 10 studies were 83 
included; outcomes with a statistically significant risk ratio greater than 2.0 was rated “large effect” and if greater than 5.0 rated “very large 84 
effect”.85 
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  86 
Supplementary Table 3. Summary of findings
Relative effect № of participants Quality of the evidence
Risk with placebo Risk with cariprazine (95% CI) (studies) (GRADE)
Discontinuation due to AEs 99 per 1,000 RR 1.13 4324 ⨁⨁◯◯
follow up: range 3 weeks to 8 weeks (68 to 146) (0.77 to 1.66) (9 RCTs) LOW 
1,2
Potentially clinically significant change in weight 39 per 1,000 RR 1.68 3912 ⨁⨁⨁⨁
follow up: range 3 weeks to 8 weeks (26 to 59) (1.12 to 2.52) (8 RCTs) HIGH
Treatment-emergent akathisia 157 per 1,000 RR 3.36 4292 ⨁⨁⨁⨁
follow up: range 3 weeks to 8 weeks (116 to 213) (2.48 to 4.56) (9 RCTs) HIGH
Treatment-emergent parkinsonism 96 per 1,000 RR 3.34 3480 ⨁⨁⨁⨁
follow up: range 3 weeks to 8 weeks (62 to 148) (2.17 to 5.13) (8 RCTs) HIGH
Use of beta-blockers medication 80 per 1,000 RR 3.71 1568 ⨁⨁⨁⨁
follow up: range 3 weeks to 6 weeks (44 to 146) (2.04 to 6.73) (4 RCTs) HIGH 
3
Use of anti-Parkinson medication 283 per 1,000 RR 2.79 1880 ⨁⨁◯◯
follow up: range 3 weeks to 6 weeks (166 to 482) (1.63 to 4.75) (5 RCTs) LOW 
1,4
Orthostatic hypotension 122 per 1,000 RR 0.93 3207 ⨁⨁⨁◯
follow up: range 3 weeks to 8 (99 to 148) (0.76 to 1.13) (7 RCTs) MODERATE 
2
1. Moderate heterogeneity (I-square > 50%) was detected
2. Number of patients included in this review is less than the optimal information size
3. Use of beta-blockers medication was used as a surrogate of adverse event of akathisia
4. Use of anti-Parkinson medication was used as a surrogate of adverse event of Parkinsonism
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effectModerate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it  is substantially 
different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very lit t le confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
102 per 1,000
131 per 1,000*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% 
CI).
47 per 1,000
29 per 1,000
22 per 1,000
Outcomes Anticipated absolute effects
*
 (95% CI) Comments
88 per 1,000
23 per 1,000
Cariprazine compared to placebo for schizophrenia or bipolar disorder
Patient or population : schizophrenia or bipolar disorder 
Setting: 
Intervention : cariprazine
Comparison : placebo
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Supplementary Table 4. Meta-analysis of other outcomes, including discontinuation and 87 
safety/tolerability outcomes 88 
Outcome No. of 
studies 
RR/Mean 
difference (95%CI) 
Heterogeneity  
Discontinuation All-cause 9 0.99 (0.87, 1.13) P=0.04, I2=50% 
Due to withdrawal 
of consent 
8 1.27 (1.03, 1.56) P=0.76, I2=0% 
Due to insufficient 
response 
8 0.64 (0.50, 0.82) P=0.25, I2=22% 
Due to SAE 5 1.32 (0.37, 4.67) P=0.07, I2=54% 
Due to loss of 
follow-up 
5 1.61 (0.82, 3.16) P=0.92, I2=0% 
Due to protocol 
violation 
5 1.22 (0.66, 2.25) P=0.63, I2=0% 
Due to mania 3 0.55 (0.24, 1.28) P=0.80, I2=0% 
Due to 
schizophrenia 
2 0.56 (0.28, 1.11) P=0.47, I2=0% 
TEAEs Total  9 1.15 (1.09, 1.21) P=0.12, I2=37% 
Insomnia 9 1.26 (0.96, 1.65) P=0.11, I2=39% 
Headache  8 0.93 (0.76, 1.13) P=0.82, I2=0% 
Nausea  9 1.57 (1.22, 2.02) P=0.89, I2=0% 
Extrapyramidal 
disorder 
8 2.49 (1.83, 3.37) P=0.50, I2=0% 
Vomiting  6 1.88 (1.28, 2.77) P=0.94, I2=0% 
Constipation  7 1.61 (1.19, 2.20) P=0.54, I2=0% 
Diarrhea  6 1.02 (0.55, 1.88) P=0.04, I2=57% 
Dizziness  5 1.64 (1.07, 2.51) P=0.73, I2=0% 
Dyspepsia  4 1.67 (0.96, 2.90) P=0.23, I2=31% 
Schizophrenia  4 0.50 (0.34, 0.74) P=0.61, I2=0% 
Sedation  3 1.56 (0.63, 3.90) P=0.10, I2=56% 
Suicidal ideation  3 0.26 (0.04, 1.73) P=0.22, I2=35% 
Somnolence  3 1.89 (1.19, 3.01) P=0.44, I2=40% 
Pyrexia  2 1.69 (0.71, 4.01) P=0.39, I2=0% 
Weight increased 2 2.88 (0.86, 9.63) P=0.96, I2=0% 
Vision blurred 2 6.79 (1.26, 36.59) P=0.96, I2=0% 
Anxiety  2 1.19 (0.68, 2.07) P=0.61, I2=0% 
Pain in extremity 2 1.19 (0.54-2.62) P=0.36, I2=0% 
Agitation 3 0.84 (0.49, 1.43) P=0.82, I2=0% 
Toothache  2 0.92 (0.25-3.43) P=0.10, I2=64% 
Irritability  2 0.54 (0.01-28.22) P=0.006, 
I2=86% 
Abdominal 
discomfort 
2 1.30 (0.58-2.94) P=0.99, I2=0% 
SAEs Total  9 0.62 (0.42, 0.91) P=0.69, I2=0% 
Mania  4 0.65 (0.21, 1.97) P=0.54, I2=0% 
Suicidal ideation  2 0.13 (0.01, 1.28) P=0.88, I2=0% 
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Liver function  PCS change in 
ALT* 
2 2.47 (0.50, 12.14) P=0.33, I2=0% 
ALT (U/L) 8 2.94 (1.38, 4.51) P=0.12, I2=38% 
AST (U/L) 8 1.03 (0.34, 1.72) P=0.44, I2=0% 
Bilirubin (total, 
mg/dL) 
8 0.01 (-0.02, 0.04) P=0.005, 
I2=66% 
AP (U/L) 5 -0.58 (-2.13, 0.98) P=0.11, I2=47% 
Vital signs Pulse (bpm) 9 0.68 (0.04, 1.32) P=0.01, I2=60% 
Waist 
circumference 
(cm) 
6 0.20 (-0.25, 0.65) P=0.33, I2=14% 
Suicidal 
ideation 
C-SSRS 
assessment 
6 0.91 (0.65, 1.27) P=0.68, I2=0% 
Medication use benzodiazepine  6 1.03 (0.98, 1.10) P=0.28, I2=20% 
AEs after 
treatment 
period 
AEs 3 0.89 (0.56, 1.42) P=0.23, I2=33% 
SAEs (psychotic 
disorder) 
3 0.18 (0.04, 0.73) P=0.56, I2=0% 
Abbreviations: AEs, adverse events; TEAEs, treatment emergent adverse events; SAEs, 89 
serious adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 90 
AP, alkaline phosphatase; C-SSRS, Columbia-Suicide Severity Rating scale; PCS, potential 91 
clinically significant; CI, confidence interval; RR=risk ratio. 92 
*PCS change in ALT was defined as ≥3 times upper limit of normal (ULN).93 
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Supplementary Table 5. Subgroup analysis by cariprazine doses 94 
Outcome Cariprazine 
dose 
No. of 
studies 
RR/Mean difference 
(95%CI) 
Heterogeneity 
between groups  
PCS weight 
change 
<6mg/day 7 1.39 (1.06, 1.83) P=0.86; I2=0% 
≥6mg/ day 4 1.46 (0.96, 2.22) 
Body weight 
(Kg) 
<6mg/day 7 0.68 (0.47, 0.89) P=0.61; I2=0% 
≥6mg/day 4 0.57 (0.18, 0.95) 
Treatment-
emergent 
akathisia 
<6mg/day 7 3.01 (2.00, 4.54) P=0.29; I2=11.5% 
≥6mg/day 4 4.16 (2.70, 6.40) 
Treatment-
emergent 
Parkinsonism 
<6mg/day 6 2.32 (1.51, 3.57) P=0.17; I2=46.5% 
≥6mg/day 4 3.67 (2.24, 6.02) 
BARS mean 
change 
<6mg/day 4 0.31 (0.22, 0.41) P=0.75; I2=0% 
≥6mg/day 4 0.35 (0.24, 0.47) 
SAS mean 
change 
<6mg/day 4 0.21 (0.02, 0.40) P=0.0010; I2=90.8% 
≥6mg/day 4 0.53 (0.50, 0.56) 
Abbreviations: PCS, potentially clinically significant; RR, risk ratio; CI, confidence interval; 95 
BARS, Barnes Akathisia Rating Scale; SAS, Simpson-Angus Scale. 96 
  97 
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Supplementary Table 6. Subgroup analysis by treatment indication 98 
 99 
Abbreviations: PCS, potential clinically significant; RR, risk ratio; CI, confidence interval; 100 
BARS, Barnes Akathisia Rating Scale; SAS, Simpson-Angus Scale. 101 
  102 
Outcome Indication No. of 
studies 
RR/Mean 
difference (95%CI) 
Heterogeneity 
between groups 
 
PCS weight 
change 
Schizophrenia 3 2.34 (1.33, 4.11) P=0.17; I2=46.3% 
 
Bipolar I 
mania 
3 1.02 (0.36, 2.91) 
 
Body weight (Kg) 
Schizophrenia 4 0.66 (0.35, 0.97) P=0.17; I2=48.1% 
 
Bipolar I 
mania 
3 0.34 (0.02, 0.67) 
Treatment-
emergent akathisia 
(BARS change) 
Schizophrenia 4 2.58 (1.65, 4.03) P=0.09; I2=66.0% 
 
Bipolar I 
mania 
3 4.49 (2.86, 7.03) 
Treatment-
emergent 
Parkinsonism  
(SAS change) 
Schizophrenia 4 2.37 (1.55, 3.62) P=0.01; I2=84.1% 
 
Bipolar I 
mania 
3 6.79 (3.35, 13.76) 
BARS mean 
change 
Schizophrenia 3 0.26 (0.13, 0.39) P=0.03; I2=80.0% 
Bipolar I 
mania 
2 0.50 (0.33, 0.67) 
SAS mean change Schizophrenia 3 0.32 (0.29, 0.36) P=0.0010; I2=90.8% 
Bipolar I 
mania 
2 0.76 (0.50, 1.01) 
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Supplementary Figure 1-1. Forest plots of all outcomes in the primary analysis: risks of treatment 103 
emergent adverse events (1) 104 
 105 
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Supplementary Figure 1-2. Forest plots of all outcomes in primary analysis: risks of treatment 106 
emergent adverse events (2) 107 
 108 
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 Supplementary Figure 1-3. Forest plots of all outcomes in primary analysis: risks of treatment 109 
emergent adverse events (3) 110 
 111 
Page 16 of 26 
 
Supplementary Figure 1-4. Forest plots of all outcomes in primary analysis: risks of treatment 112 
emergent adverse events (4) 113 
 114 
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Supplementary Figure 1-5. Forest plots of all outcomes in primary analysis: risks of severe 115 
adverse events 116 
 117 
  118 
Page 18 of 26 
 
Supplementary Figure 1-6. Forest plots of all outcomes in primary analysis: risks of 119 
discontinuation of treatment (1) 120 
 121 
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Supplementary Figure 1-7. Forest plots of all outcomes in primary analysis: risks of 122 
discontinuation of treatment (2) 123 
 124 
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Supplementary Figure 1-8. Forest plots of all outcomes in primary analysis: risk of potentially 125 
clinically significant change of laboratory parameters 126 
 127 
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Supplementary Figure 1-9. Forest plots of all outcomes in primary analysis: mean changes from 128 
baseline in vital signs 129 
 130 
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Supplementary Figure 1-10. Forest plots of all outcomes in primary analysis: mean changes from 131 
baseline in liver function parameters 132 
 133 
  134 
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Supplementary Figure 1-11. Forest plots of all outcomes in primary analysis: mean changes from 135 
baseline in metabolic parameters 136 
 137 
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Supplementary Figure 1-12. Forest plots of all outcomes in primary analysis: mean changes from 138 
baseline in psychiatric scales 139 
 140 
  141 
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Supplementary Figure 1-13. Forest plots of all outcomes in primary analysis: risks of use of 142 
rescue medication for adverse events 143 
 144 
Abbreviations: EPS, extrapyramidal side effects; AIMS, Abnormal Involuntary Movement Scale; 145 
AE, adverse event; TEAE, treatment emergent adverse event; SAE, serious adverse event; ALT, 146 
alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; C-SSRS, 147 
Columbia-Suicide Severity Rating scale; PCS, potential clinically significant; CI, confidence 148 
interval; RR, risk ratio; BARS, Barnes Akathisia Rating Scale; SAS, Simpson-Angus Scale; LDL, 149 
low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure; DBP, 150 
diastolic blood pressure. 151 
